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Anticoagulation with argatroban in patients with heparin-induced
thrombocytopenia antibodies after cardiovascular surgery with
cardiopulmonary bypass: First results from the ARG-E03 trial
Andreas Koster, MD,a Semi Buz, MD,b Roland Hetzer, MD,b Hermann Kuppe, MD,a Klaus Breddin, MD,c and
Sebastian Harder, MD,d Berlin and Frankfurt/Main, Germany
Heparin-induced thrombocytopenia (HIT) is a severethrombogenic disease requiring the use of alternativeanticoagulants. Argatroban is a synthetic monovalentdirect thrombin inhibitor hepatically metabolized with
a 45-minute half-life.1 Argatroban is the only anticoagulant indi-
cated for prophylaxis and treatment of thrombosis in patients with
HIT. However, there are scant data regarding use of argatroban in
patients with HIT after cardiovascular surgery with cardiopulmo-
nary bypass (CPB). We report on postoperative argatroban in 14
patients with HIT antibodies who underwent cardiovascular sur-
gery with CPB.
Patients and Methods
The European ARG-E03 trial is a multicenter, open-label trial
assessing argatroban as a replacement for heparin in patients with
a history of HIT or suspected HIT. After ethics committee ap-
proval and having obtained informed consent, we enrolled 20
patients from our center. Four patients underwent procedures with-
out CPB. Two of the patients undergoing CPB were treated ac-
cording to the original protocol with an argatroban starting dose of
2 g · kg1 · min1, and an activated partial thromboplastin
time (aPTT) overshoot to values exceeding 80 seconds was ob-
served. Therefore the starting dose was reduced to 0.8 to 1 g ·
kg1 · min1 for further patients. We report on the 14 patients
who underwent CPB procedures with this protocol.
Results
There were 9 female and 5 male patients with HIT antibodies
present before surgical intervention, with a mean age of 61.2 
14.7 years and mean weight of 78.0  16.6 kg. Surgical interven-
tion was coronary artery bypass grafting in 6 patients, coronary
artery bypass grafting plus valve repair-replacement in 3 patients,
valve surgery only in 4 patients, and repair of a descending
thoracic aortic aneurysm in 1 patient. Anticoagulation during CPB
had been performed with heparin and tirofiban; postoperative
argatroban anticoagulation was initiated immediately after surgical
intervention, with a target aPTT of 50 to 70 seconds (STA aPTT,
Roche; normal value, 20-22 seconds). Patients were maintained on
argatroban anticoagulation for the routine duration of intravenous
therapy. In patients without valve surgery (n  7), anticoagulation
was changed to single subcutaneous injection of 15 mg/d desirudin
(Revasc, Canyon Pharma, Hunt Valley, Md) starting the day after
the operation. In patients after valve repair (n 4), anticoagulation
was continued with argatroban for 3 days and thereafter changed to
desirudin and then to warfarin sodium (Marcumar, Roche, Rein-
ach, Switzerland). In 2 patients after valve replacement, argatroban
was transited to warfarin sodium. In 2 patients who reacted rather
sensitively to argatroban (0.2 g · kg1 · min1), the switch
was made to lepirudin (Refludan, Hoechst Marion Roussel, Kansas
City, Mo). However, in these patients the lepirudin requirement
was also quite low (0.001 mg · kg1 · h1). The mean
duration of drug administration was 3.0  1.2 days. In all patients
the initial infusion rate achieved target aPTT within 30 minutes,
and in all patients, this target aPTT could be maintained without a
further increase of the dose. Instead, reduction of the dose to an
average of 0.3 to 0.4 g · kg1 · min1 was performed in most
patients (Table 1 and Figure 1).
The clinical course of 13 patients was unremarkable, and mean
postoperative blood loss was 210 54 mL in the first hour, 167
37 mL in the second hour, and 765  623 mL at 24 hours
postoperatively. There were 27 units of red packed blood cells, 1
From the Departments of Anesthesiaa and Cardiothoracic and Vascular
Surgery,b Deutsches Herzzentrum Berlin, Berlin, Germany; International
Institute of Thrombosis and Vascular Diseases,c Frankfurt/Main, Germany;
and the Department of Clinical Pharmacology,d Klinikum, J.W. Goethe-
Universität, Frankfurt/Main, Germany.
Andreas Koster, Sebastian Harder, and HK Breddin report lecture fees from
Mitsubishi Pharma. This study was supported by a grant from Mitsubishi
Pharma Deutschland GmbH, the manufacturer of argatroban.
Received for publication March 16, 2006; revisions received April 5, 2006;
accepted for publication April 25, 2006.
Address for reprints: Andreas Koster, MD, Deutsches Herzzentrum Berlin,
Augustenburger Platz 1, D-13353 Berlin (E-mail: koster@dhzb.de).
J Thorac Cardiovasc Surg 2006;132:699-700
0022-5223/$32.00
Copyright © 2006 by The American Association for Thoracic Surgery
doi:10.1016/j.jtcvs.2006.04.034
TABLE 1. Mean aPTT values at different time points
B S0.5 S2 S4 D2 D3 E0 E2 E4
aPTT (s) 40 14 58  14 65  14 65  14 58  12 64  10 61  14 49  14 45  11
Patient numbers were as follows: 14 at B to S4, 12 at D2, 10 at D3, and 14 at E0. aPTT, Activated partial thromboplastin time; B, baseline value before
argatroban infusion; S0.5, 30 minutes after start of argatroban; S2, 2 hours after start of argatroban; S4, 4 hours after start of argatroban; D2, day 2; D3,
day 3; E0, before termination of argatroban infusion; E2, 2 hours after termination; E4, 4 hours after termination.
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random donor platelet concentrate, and 22 units of fresh frozen
plasma transfused postoperatively in 9 patients. In 5 patients no
transfusions were necessary postoperatively. In 1 patient increased
postoperative hemorrhage was observed (550 mL in the first hour,
480 mL in the second hour, and 2780 mL in 24 hours), and the
argatroban infusion was stopped because the aPTT exceeded 80
seconds. After the bleeding stopped, the argatroban infusion was
again started, and the further course of the patient was uneventful.
Discussion
In previous studies of patients with HIT in a non-CPB setting,
argatroban therapy was initiated with 2 g · kg1 · min1, and
the mean doses necessary to achieve target aPTTs ranged between
1.7 and 2.0 g · kg1 · min1.2,3 In approximately 10% of these
patients, a maximum dose of 10 g · kg1 · min1 failed to
achieve the target aPTTs.2 In contrast, in a case series of 4 patients
with HIT after cardiac surgery, excessive anticoagulation to aPTT
values of greater than 100 seconds using the starting doses of 2 and
1 g · kg1 · min1 has been reported.4
The starting dose of 0.8 to 1 g · kg1 · min1 argatroban
provided rapid anticoagulation to target aPTTs within 30 minutes
in all patients, and in most patients, it was later reduced to rates of
less than 0.5 g · kg1 · min1 (Figure 1). After termination of
argatroban, a marked decrease of aPTT was observed within 4
hours, indicating rapid fading of the anticoagulant effect (Table 1).
Different aPTT assays demonstrate significant variations re-
garding the response to argatroban.5 This might explain the large
variation in patients’ response to argatroban observed in the ARG
911 and ARG 915 investigations and has to be considered when
evaluating our single-center data.
We conclude that in patients with HIT antibodies after cardio-
vascular surgery with CPB, argatroban given at a starting dose of
0.8 to 1 g · kg1 · min1 provides rapid and effective antico-
agulation without the need for bolus administration and almost
exclusively without dramatic overshoot of the aPTT. However, the
fact that this dose had to be reduced during the further course
suggests that this patient population reacts sensitively to argatro-
ban, and tight monitoring, particularly during the initiation of
therapy, is recommended.
In conclusion, we have shown that argatroban provides rapid
and effective anticoagulation in patients with HIT antibodies after
cardiovascular surgery with CPB and that argatroban was safely
used in the patients studied. However, further studies are needed to
define in greater detail the safety profile of argatroban in critical
indications.
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Figure 1. Mean dose of argatro-
ban in the ARG 915 and ARG 911
study patients and the current
investigation. HIT, Patients with
heparin-induced thrombocyto-
penia without thromboembo-
lism; HITT, patients with hepa-
rin-induced thrombocytopenia
and concomitant thromboembo-
lism. Current study data: S0.5, 30
minutes after start of argatro-
ban; S2, 2 hours after start; S4, 4
hours after start; D1, end of first
day; D2, day 2; D3, day 3; E0,
before termination of argatroban
infusion. Patient numbers were
as follows: 14 at S0.5 to D1, 12 at
D2, 10 at D3, and 14 at E0.
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